Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 160724, 21 pages
http://dx.doi.org/10.1155/2012/160724
Review Article

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

1Research Service, VA Long Beach Healthcare System, 5901 E. 7th Street, Long Beach, CA 90822, USA
2Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA 92697, USA
3Chao Family Comprehensive Cancer Center, UC Irvine School of Medicine, University of California, Irvine, Orange, CA 92868, USA
4Health Care Group, Department of Diagnostic and Molecular Medicine, Pathology and Laboratory Medicine Service, VA Long Beach Healthcare System, 5901 East 7th Street, Box 113, Long Beach, CA 90822, USA

Received 7 March 2012; Revised 29 April 2012; Accepted 30 April 2012

Academic Editor: Nejat Egilmez

Copyright © 2012 Martin R. Jadus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [38 citations]

The following is the list of published articles that have cited the current article.

  • Marlies E. Heuvers, Joost P. Hegmans, Bruno H. Stricker, and Joachim G. Aerts, “Improving lung cancer survival; time to move on,” Bmc Pulmonary Medicine, vol. 12, 2012. View at Publisher · View at Google Scholar
  • Marlies E. Heuvers, Femke Muskens, Koen Bezemer, Margaretha Lambers, Anne-Marie C. Dingemans, Harry J.M. Groen, Egbert F. Smit, Henk C. Hoogsteden, Joost P.J.J. Hegmans, and Joachim G.J.V. Aerts, “Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients,” Lung Cancer, 2013. View at Publisher · View at Google Scholar
  • N. Catherine Sánchez, “Conociendo y comprendiendo la célula cancerosa: Fisiopatología del cáncer,” Revista Médica Clínica Las Condes, vol. 24, no. 4, pp. 553–562, 2013. View at Publisher · View at Google Scholar
  • Yu Li, Jun-Fei Gu, Xi Zou, Jian Wu, Ming-Hua Zhang, Jun Jiang, Dong Qin, Jin-Yong Zhou, Bao-Xin-Zi Liu, Yun-Tao Zhu, Xiao-Bin Jia, Liang Feng, and Rui-Ping Wang, “The Anti-Lung Cancer Activities of Steroidal Saponins of P. polyphylla Smith var. chinensis (Franch.) Hara through Enhanced Immunostimulation in Experimental Lewis Tumor-Bearing C57BL/6 Mice and Induction of Apoptosis in the A549 Cell Line,” Molecules, vol. 18, no. 10, pp. 12916–12936, 2013. View at Publisher · View at Google Scholar
  • Ai-Ling Liang, Ting-Ting Zhang, Ning Zhou, Di-Nan Huang, Xin-Guang Liu, and Yong-Jun Liu, “Fused Polypeptide with DEF Induces Apoptosis of Lung Adenocarcinoma Cells,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 12, pp. 7339–7344, 2013. View at Publisher · View at Google Scholar
  • Anish Thomas, and Marko Jakopovic, “Immunotherapy for non-small-cell lung cancer,” Expert Opinion on Biological Therapy, pp. 1–4, 2014. View at Publisher · View at Google Scholar
  • R D Harvey, “Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer,” Clinical Pharmacology & Therapeutics, 2014. View at Publisher · View at Google Scholar
  • Marianne Davies, “New modalities of cancer treatment for NSCLC: Focus on immunotherapy,” Cancer Management and Research, vol. 6, no. 1, pp. 63–75, 2014. View at Publisher · View at Google Scholar
  • Ana María Hernández, and Ana María Vázquez, “Racotumomab–alum vaccine for the treatment of non-small-cell lung cancer,” Expert Review of Vaccines, pp. 1–12, 2014. View at Publisher · View at Google Scholar
  • Mauricio Burotto, Anish Thomas, Deepa Subramaniam, Giuseppe Giaccone, and Arun Rajan, “Biomarkers in Early-Stage Non–Small-Cell Lung Cancer,” Journal of Thoracic Oncology, vol. 9, no. 11, pp. 1609–1617, 2014. View at Publisher · View at Google Scholar
  • Jacek R. Wilczynski, and Marek Nowakpp. 143–205, 2014. View at Publisher · View at Google Scholar
  • Yan Xu, and Mengzhao Wang, “Progress in immunotherapy for non-small cell lung cancer,” Chinese Journal of Lung Cancer, vol. 17, no. 1, pp. 34–41, 2014. View at Publisher · View at Google Scholar
  • Ana Miar, David Hevia, Henar Munoz-Cimadevilla, Aurora Astudillo, Julio Velasco, Rosa M. Sainz, and Juan C. Mayo, “Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and l,” Free Radical Biology And Medicine, vol. 85, pp. 45–55, 2015. View at Publisher · View at Google Scholar
  • Sacha I. Rothschild, “Advanced and metastatic lung cancer - What is new in the diagnosis and therapy?,” Praxis, vol. 104, no. 14, pp. 745–750, 2015. View at Publisher · View at Google Scholar
  • Li-Sheng Ge, Neil T. Hoa, Nils Lambrecht, Maria Dacosta-Iyer, Yi Ouyang, Amir Abolhoda, and Martin R. Jadus, “Changes in tumor-antigen expression profile as human small-cell lung cancers progress,” Cancer Biology and Medicine, vol. 12, no. 2, pp. 96–105, 2015. View at Publisher · View at Google Scholar
  • Vidhya V. Iyer, “Small molecules for immunomodulation in cancer: A review,” Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 4, pp. 433–452, 2015. View at Publisher · View at Google Scholar
  • G.V. Scagliotti, P. Bironzo, and J.F. Vansteenkiste, “Addressing the unmet need in lung cancer: the potential of immuno-oncology,” Cancer Treatment Reviews, 2015. View at Publisher · View at Google Scholar
  • Ana Miar, David Hevia, Henar Muñoz-Cimadevilla, Aurora Astudillo, Julio Velasco, Rosa M. Sainz, and Juan C. Mayo, “Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon and lung cancer,” Free Radical Biology and Medicine, 2015. View at Publisher · View at Google Scholar
  • Abhisek Swaika, William A. Hammond, and Richard W. Joseph, “Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy,” Molecular Immunology, 2015. View at Publisher · View at Google Scholar
  • Eleanor Jones, Christos Mikropoulos, and Mahbubl Ahmed, “The future of immunotherapy in the treatment of lung cancer,” Lung Cancer Management, pp. 1–17, 2015. View at Publisher · View at Google Scholar
  • Martin Reck, and Luis Paz-Ares, “Immunologic Checkpoint Blockade in Lung Cancer,” Seminars in Oncology, 2015. View at Publisher · View at Google Scholar
  • Nitin Chakravarti, and Victor G. Prieto, “Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: Immunohistochemistry analysis,” Translational Lung Cancer Research, vol. 4, no. 6, pp. 743–751, 2015. View at Publisher · View at Google Scholar
  • Colleen Lewis, “Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies,” Clinical Journal of Oncology Nursing, vol. 20, no. 3, pp. 319–326, 2016. View at Publisher · View at Google Scholar
  • Dickson Adah, Muzammal Hussain, Limei Qin, Li Qin, Jiancun Zhang, and Xiaoping Chen, “Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics,” Pharmacological Research, 2016. View at Publisher · View at Google Scholar
  • Filippos Koinis, Eleni Kyriaki Vetsika, Despoina Aggouraki, Eleftheria Skalidaki, Anna Koutoulaki, Marianthi Gkioulmpasani, Vassilis Georgoulias, and Athanasios Kotsakis, “Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer,” Journal of Thoracic Oncology, 2016. View at Publisher · View at Google Scholar
  • Francesco Passiglia, Daniele Santini, Viviana Bazan, Antonio Galvano, Angela Listì, Antonio Russo, Giuseppe Bronte, Clara Natoli, Sergio Rizzo, Giuseppe Cicero, and Christian Rolfo, “PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis,” Oncotarget, vol. 7, no. 15, pp. 19738–19747, 2016. View at Publisher · View at Google Scholar
  • Xiaoxia Xin, Lihong Zhang, Yongsen Mo, Hui Zhu, Jing Li, Yan Pang, and Jiali Li, “A comparison of clinical outcomes between radiotherapy and autoimmune cells therapy in non-small cell lung cancer patients,” Cancer Treatment and Research Communications, vol. 9, pp. 116–120, 2016. View at Publisher · View at Google Scholar
  • Kristen A. Marrone, and Julie R. Brahmer, “Immune Checkpoint Therapy in Non–Small Cell Lung Cancer,” The Cancer Journal, vol. 22, no. 2, pp. 81–91, 2016. View at Publisher · View at Google Scholar
  • 鑫辉 江, “Advances in Immune Therapy for Non Small Cell Lung Cancer,” Medical Diagnosis, vol. 06, no. 01, pp. 15–20, 2016. View at Publisher · View at Google Scholar
  • Yueya Li, Cuicui Zhang, Xiyin Wei, Xinyue Wang, and Kai Li, “Base amount of blood T-lymphocyte subsets and NK cells in patients with lung cancer and its value in predicting prognosis,” Chinese Journal of Clinical Oncology, vol. 43, no. 5, pp. 204–210, 2016. View at Publisher · View at Google Scholar
  • Yeonghun Lee, Sehhoon Park, Se-Hoon Lee, and Hyunju Lee, “Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma,” BMC Cancer, vol. 17, no. 1, 2017. View at Publisher · View at Google Scholar
  • Mozhi Wang, Yingying Xu, Zhenning Wang, Yaojia Wang, Fang Luo, Changwang Zhang, Yongxi Song, Yujie Xu, Yi Zhao, and Zhonghua Wu, “Mechanism of immune evasion in breast cancer,” OncoTargets and Therapy, vol. 10, pp. 1561–1573, 2017. View at Publisher · View at Google Scholar
  • Anne-Sophie Gautron, Alexandre Juillerat, Valérie Guyot, Jean-Marie Filhol, Emilie Dessez, Aymeric Duclert, Philippe Duchateau, and Laurent Poirot, “Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy,” Molecular Therapy - Nucleic Acids, vol. 9, pp. 312–321, 2017. View at Publisher · View at Google Scholar
  • Rosalyn A. Juergens, Katherine A. Zukotynski, Amit Singnurkar, Denis P. Snider, John F. Valliant, and Karen Y. Gulenchyn, “Imaging Biomarkers in Immunotherapy,” Biomarkers in Cancer, vol. 8s2, pp. BIC.S31805, 2017. View at Publisher · View at Google Scholar
  • Na Qin, Cheng Wang, Meng Zhu, Qun Lu, Zijian Ma, Mingtao Huang, Juncheng Dai, Hongxia Ma, Guangfu Jin, Zhibin Hu, and Hongbing Shen, “Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer,” Lung Cancer, vol. 112, pp. 169–175, 2017. View at Publisher · View at Google Scholar
  • Xueyan Zhang, Huimin Wang, Xiaoxuan Zheng, Yuqing Lou, Yanwei Zhang, Jianlin Xu, and Baohui Han, “Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells,” Journal of Cancer, vol. 9, no. 2, pp. 367–374, 2017. View at Publisher · View at Google Scholar
  • Hongliu Sun, Hongyu Zhang, Haiqing Ma, Jianjun Tang, Huanhuan Sun, Xiaobin Zheng, Zhanyu Li, Jie Li, Shuncong Wang, Cuiling Zhou, Zhibin Cheng, Tiantian Sun, and Xiuling Zhou, “PD-L1 expression as poor prognostic factor in patients with nonsquamous non-small cell lung cancer,” Oncotarget, vol. 8, no. 35, pp. 58457–58468, 2017. View at Publisher · View at Google Scholar
  • Shifaa Abdin, Dana Zaher, El-Shaimaa Arafa, and Hany Omar, “Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors,” Cancers, vol. 10, no. 2, pp. 32, 2018. View at Publisher · View at Google Scholar